Premium
Continuous Flow Homolytic Aromatic Substitution with Electrophilic Radicals: A Fast and Scalable Protocol for Trifluoromethylation
Author(s) -
Monteiro Júlia L.,
Carneiro Paula F.,
Elsner Petteri,
Roberge Dominique M.,
Wuts Peter G. M.,
Kurjan Katherine C.,
Gutmann Bernhard,
Kappe C. Oliver
Publication year - 2017
Publication title -
chemistry – a european journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.687
H-Index - 242
eISSN - 1521-3765
pISSN - 0947-6539
DOI - 10.1002/chem.201604579
Subject(s) - chemistry , trifluoromethylation , homolysis , trifluoromethyl , electrophile , radical , reagent , dihydroergotamine , electrophilic aromatic substitution , reactivity (psychology) , medicinal chemistry , combinatorial chemistry , photochemistry , organic chemistry , catalysis , medicine , alkyl , alternative medicine , pathology , migraine
We report an operationally simple and rapid continuous flow radical C−C bond formation under Minisci‐type reaction conditions. The transformations are performed at or below room temperature employing hydrogen peroxide (H 2 O 2 ) and dimethylsulfoxide (DMSO) as reagents in the presence of an Fe II catalyst. For electron‐rich aromatic and heteroaromatic substrates, C−C bond formation proceeds satisfactorily with electrophilic radicals including . CF 3 , . C 4 F 9 , . CH 2 CN, and . CH 2 CO 2 Et. In contrast, electron‐poor substrates exhibit minimal reactivity. Importantly, trifluoromethylations and nonafluororobutylations using CF 3 I and C 4 F 9 I as reagents proceed exceedingly fast with high conversion for selected substrates in residence times of a few seconds. The attractive features of the present process are the low cost of the reagents and the extraordinarily high reaction rates. The direct application of the protocol to dihydroergotamine, a complex ergot alkaloid, yielded the corresponding trifluoromethyl ergoline derivative within 12 seconds in a continuous flow microreactor on a 0.6 kg scale. The trifluoromethyl derivative of dihydroergotamine is a promising therapeutic agent for the treatment of migraines.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom